


GNE-0877

11/19

ALTERNATE NAMES: 2-methyl-2-[3-methyl-4-[[4-(methylamino)-5-(trifluoromethyl)pyrimidin-2-yl]amino]pyrazol-1-yl]propanenitrile; $\alpha, \alpha, 3$ -trimethyl-4-[[4-(methylamino)-5-(trifluoromethyl)-2-pyrimidinyl]amino]-1H-pyrazole-1-acetonitrile

CATALOG #: B2942-1 1 mg
B2942-5 5 mg

STRUCTURE:



MOLECULAR FORMULA: C₁₄H₁₆F₃N₇

MOLECULAR WEIGHT: 339.32

CAS NUMBER: 1374828-69-9

APPEARANCE: A crystalline solid

PURITY: 98.64%

SOLUBILITY: ~15 mg/ml DMSO
~1 mg/ml in ethanol
~10 mg/ml in DMF

DESCRIPTION: GNE-0877 is a selective, brain-penetrable Leucine-rich repeat kinase 2 (LRRK2) inhibitor with a K_i of 0.7 nM. Mutations in LRRK2 are associated with Parkinson's disease. GNE-0877 inhibits LRRK2 Ser1292 autophosphorylation in BAC transgenic mice expressing human LRRK2 protein with the G2019S Parkinson's disease mutation with an IC₅₀ value of 3 nM.

STORAGE TEMPERATURE: -20°C

HANDLING: Do not take internally. Wear gloves and mask when handling the product! Avoid contact by all modes of exposure.

REFERENCE: Estrada, A.A., Chan, B.K., Baker-Glenn, C., et al. Discovery of highly potent, selective, and brain-penetrant aminopyrazole leucine-rich repeat kinase 2 (LRRK2) small molecule inhibitors. *Journal of Medicinal Chemistry* 57(3), 921-936 (2014).

RELATED PRODUCTS:

LRRK2-IN-1 (Cat. No. B2940)
GSK2578215A (Cat. No. 2845)
HG-10-012-01 (Cat. No. 2604)
PF-06447475 (Cat. No. 9447)
CZC-25146 (Cat. No. B2941)

DISCLAIMER: ***FOR RESEARCH USE ONLY! Not to be used on humans.***